Invivyd Inc., based in Waltham, Massachusetts, has announced an underwritten public offering of its common stock. The company plans to grant underwriters a 30-day option to purchase an additional 15% of the shares sold, at the public offering price, minus underwriting discounts and commissions. Cantor is acting as the sole book-running manager for this offering. Invivyd intends to use the net proceeds from the offering to support trial protocol development, advance the VYD2311 clinical program, conduct research and development for its pipeline programs, such as RSV and measles, and further initiatives related to monoclonal antibody therapy for Long COVID and COVID-19 Post-Vaccination Syndrome. The offering is subject to market conditions, and its completion or final terms have not been guaranteed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.